Aura Biosciences, Inc. Stock Price, News & Analysis

Aura Biosciences (NASDAQ: AURA) announced FDA Fast Track Designation for belzupacap sarotalocan (bel-sar) to treat choroidal metastasis, signifying a significant opportunity for a new standard of care. Following positive Phase 2 results for early-stage choroidal melanoma, the global Phase 3 trial is set to begin dosing in 1H 2023. Financial results reveal a cash position of $188.8 million, sufficient to fund operations into 2025.

However, R&D expenses surged to $42.2 million, contributing to a net loss of $58.8 million for the year.

Aura Biosciences, Inc. (Nasdaq: AURA) announced positive interim Phase 2 safety and efficacy data for its treatment, bel-sar, aimed at early-stage choroidal melanoma. Results showed an impressive 100% tumor control rate and an 88% visual acuity preservation rate after an average of nine months follow-up in patients. The therapy demonstrated favorable safety, with only one case of visual acuity loss and no serious adverse events reported. Aura plans to initiate a global Phase 3 trial this year, bolstering confidence in bel-sar's potential as a first-line treatment. These results were presented at the Macula Society’s 46th Annual Meeting in Miami, FL.

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotech firm, focuses on developing virus-like drug conjugate (VDC) therapies for oncology. CEO Elisabet de los Pinos will present at the SVB Securities Global Biopharma Conference on February 16, 2023 at 12:00 p.m. ET and at the 43rd Annual Cowen Healthcare Conference on March 8, 2023, participating in an auditory and ophthalmology panel at 12:50 p.m. ET. These events will be accessible via live webcasts on Aura's website, where replays will be available for 90 days.

Aura's lead VDC candidate, bel-sar, targets ocular cancers and is in a Phase 3 trial for treating early-stage choroidal melanoma.

Aura Biosciences, Inc. has announced the pricing for an underwritten public offering of 6,700,000 shares of its common stock at $12.00 per share, aiming to raise gross proceeds of approximately $80.4 million. The offering is expected to close by December 5, 2022, pending customary closing conditions. Aura has also offered underwriters a 30-day option to purchase up to 1,005,000 additional shares. This capital is intended to support the development of its virus-like drug conjugate therapies targeting multiple oncology indications, particularly for ocular cancers.

Aura Biosciences, Inc. (NASDAQ: AURA) announced an underwritten public offering of its common stock, with all shares being offered by the company. The offering is subject to market conditions, and underwriters may purchase an additional 15% of shares. The offering follows a shelf registration statement filed with the SEC. Aura is focused on developing virus-like drug conjugate therapies for various oncology indications, including a global Phase 3 trial for treating choroidal melanoma.

Aura Biosciences reported its Q3 2022 financial results, highlighting significant clinical advancements in its oncology programs. The company announced the global Phase 3 trial design for belzupacap sarotalocan in treating early-stage choroidal melanoma, marking a milestone in vision-preserving therapy. A first patient has been dosed in a Phase 1 study for non-muscle invasive bladder cancer. Financially, Aura’s cash position is $111.5 million, expected to fund operations until 2024. However, R&D and G&A expenses have increased, leading to a net loss of $15.9 million for Q3 2022.

Aura Biosciences Inc. (NASDAQ: AURA) has announced the initiation of startup activities for a global Phase 3 trial for its drug belzupacap sarotalocan (bel-sar), aimed at treating early-stage choroidal melanoma. This follows positive interim data from a Phase 2 trial presented at the American Academy of Ophthalmology. The trial will evaluate bel-sar's safety and efficacy compared to a sham treatment. Approximately 75 patients will be enrolled, with a focus on those with documented tumor growth to enhance trial efficiency.

Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company, announced participation in key investor conferences. The executive team will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 10:55 a.m. ET, and hold a fireside chat at the 5th Annual 2022 Evercore ISI HealthCONx on November 29, 2022, at 8:25 a.m. ET. Webcasts of both events will be accessible on the company’s website for 90 days post-event. Aura specializes in virus-like drug conjugates for various oncology treatments, including ocular cancers.